Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	141.21	106.14	101.42	112.51	106.01
Depreciation & Amortization	1.34	2.36	3.45	3.48	2.24
Loss (Gain) From Sale of Investments	-10.94	-9.13	1.38	-	-
Stock-Based Compensation	61.35	48.94	42.44	42.93	33.54
Other Operating Activities	-40.19	-29.49	-33.91	9.44	15.54
Change in Accounts Receivable	-12.85	-10.07	-3.43	-1.43	-6.27
Change in Inventory	0.31	1.27	1.2	3.44	-3.51
Change in Accounts Payable	-2.25	5.78	4.76	-3.6	3.16
Change in Income Taxes	3.78	1.21	8.69	0.01	0.01
Change in Other Net Operating Assets	56.32	10.03	-5.67	1.1	1.25
Operating Cash Flow	198.07	127.04	120.32	167.89	151.97
Operating Cash Flow Growth	55.91%	5.58%	-28.33%	10.48%	11.65%
Capital Expenditures	-2.17	-0.14	-0.41	-0.47	-1.24
Investment in Securities	-175.43	91.05	-113.91	136.6	-118.03
Investing Cash Flow	-177.6	90.91	-114.33	136.13	-119.26
Issuance of Common Stock	9.62	5.81	4.38	16.23	23.23
Repurchase of Common Stock	-37.97	-154.53	-21.67	-318.82	-11.01
Financing Cash Flow	-28.35	-148.72	-17.28	-302.59	12.21
Net Cash Flow	-7.89	69.22	-11.29	1.43	44.92
Free Cash Flow	195.9	126.9	119.91	167.42	150.73
Free Cash Flow Growth	54.37%	5.83%	-28.38%	11.07%	11.63%
Free Cash Flow Margin	29.02%	26.31%	29.84%	45.75%	42.59%
Free Cash Flow Per Share	1.73	1.14	1.03	1.33	1.21
Cash Income Tax Paid	60.27	47.6	39.75	9.1	10.86
Levered Free Cash Flow	183.85	128.39	115.55	120.18	116.42
Unlevered Free Cash Flow	183.85	128.39	115.55	120.18	116.42
Change in Net Working Capital	-37.74	-10.17	0.32	3.55	-1.75

Source: S&P Capital IQ. Standard template. Financial Sources.